116 related articles for article (PubMed ID: 21177113)
1. Predicting the yield of (177)Lu radionuclide produced by the cyclic irradiation technique.
Odame Duodu G; Akaho EH; Serfor-Armah Y; Nyarko BJ; Afi Achoribo E
Appl Radiat Isot; 2011 Mar; 69(3):588-93. PubMed ID: 21177113
[TBL] [Abstract][Full Text] [Related]
2. Production of 177Lu at the new research reactor FRM-II: Irradiation yield of 176Lu(n,gamma)177Lu.
Dvorakova Z; Henkelmann R; Lin X; Türler A; Gerstenberg H
Appl Radiat Isot; 2008 Feb; 66(2):147-51. PubMed ID: 17900914
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study for production of I-131 radioisotope using MNSR research reactor.
Elom Achoribo AS; Akaho EH; Nyarko BJ; Osae Shiloh KD; Odame Duodu G; Gibrilla A
Appl Radiat Isot; 2012 Jan; 70(1):76-80. PubMed ID: 21900016
[TBL] [Abstract][Full Text] [Related]
4. Target burn-up corrected specific activity of 177Lu produced via 176Lu(n, gamma) 177Lu nuclear reactions.
Zhernosekov KP; Perego RC; Dvorakova Z; Henkelmann R; Türler A
Appl Radiat Isot; 2008 Sep; 66(9):1218-20. PubMed ID: 18359234
[TBL] [Abstract][Full Text] [Related]
5. The feasibility study of
Golabian A; Hosseini MA; Ahmadi M; Soleimani B; Rezvanifard M
Appl Radiat Isot; 2018 Jan; 131():62-66. PubMed ID: 29173809
[TBL] [Abstract][Full Text] [Related]
6. [A new correction method for radionuclide formation in neutron activation analysis using a reactor power meter coupled with a microcomputer].
Hirai S; Yoshino Y; Suzuki S; Horiuchi N
Radioisotopes; 1982 May; 31(5):229-34. PubMed ID: 7134499
[TBL] [Abstract][Full Text] [Related]
7. Production of No-Carrier Added Lutetium-177 by Irradiation of Enriched Ytterbium-176.
Tarasov VA; Andreev OI; Romanov EG; Kuznetsov RA; Kupriyanov VV; Tselishchev IV
Curr Radiopharm; 2015; 8(2):95-106. PubMed ID: 25771378
[TBL] [Abstract][Full Text] [Related]
8. Characterization of neutron flux spectra in irradiation sites of MNSR reactor using the Westcott-formalism for the k0 neutron activation analysis method.
Akaho EH; Nyarko BJ
Appl Radiat Isot; 2002 Aug; 57(2):265-73. PubMed ID: 12150286
[TBL] [Abstract][Full Text] [Related]
9. Activation of natural Hf and Ta in relation to the production of 177Lu.
Medvedev DG; Mausner LF; Greene GA; Hanson AL
Appl Radiat Isot; 2008 Oct; 66(10):1300-6. PubMed ID: 18456503
[TBL] [Abstract][Full Text] [Related]
10. Cross-section measurement of the 169 Tm p,n reaction for the production of the therapeutic radionuclide 169 Yb and comparison with its reactor-based generation.
Spahn I; Takács S; Shubin YN; Tárkányi F; Coenen HH; Qaim SM
Appl Radiat Isot; 2005 Aug; 63(2):235-9. PubMed ID: 15919210
[TBL] [Abstract][Full Text] [Related]
11. Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin.
Moustapha ME; Ehrhardt GJ; Smith CJ; Szajek LP; Eckelman WC; Jurisson SS
Nucl Med Biol; 2006 Jan; 33(1):81-9. PubMed ID: 16459262
[TBL] [Abstract][Full Text] [Related]
12. Physical optimization of production by deuteron irradiation of high specific activity (177g)Lu suitable for radioimmunotherapy.
Manenti S; Bonardi ML; Gini L; Groppi F
Nucl Med Biol; 2014; 41(5):407-9. PubMed ID: 24666720
[TBL] [Abstract][Full Text] [Related]
13. The low-energy β(-) and electron emitter (161)Tb as an alternative to (177)Lu for targeted radionuclide therapy.
Lehenberger S; Barkhausen C; Cohrs S; Fischer E; Grünberg J; Hohn A; Köster U; Schibli R; Türler A; Zhernosekov K
Nucl Med Biol; 2011 Aug; 38(6):917-24. PubMed ID: 21843788
[TBL] [Abstract][Full Text] [Related]
14. Excitation function for deuteron induced nuclear reactions on natural ytterbium for production of high specific activity 177g Lu in no-carrier-added form for metabolic radiotherapy.
Manenti S; Groppi F; Gandini A; Gini L; Abbas K; Holzwarth U; Simonelli F; Bonardi M
Appl Radiat Isot; 2011 Jan; 69(1):37-45. PubMed ID: 20801665
[TBL] [Abstract][Full Text] [Related]
15. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment.
Knapp FF; Beets AL; Guhlke S; Zamora PO; Bender H; Palmedo H; Biersack HJ
Anticancer Res; 1997; 17(3B):1783-95. PubMed ID: 9179235
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic radionuclides: production and decay property considerations.
Volkert WA; Goeckeler WF; Ehrhardt GJ; Ketring AR
J Nucl Med; 1991 Jan; 32(1):174-85. PubMed ID: 1988628
[TBL] [Abstract][Full Text] [Related]
17. Large-scale production of lutetium-177m for the
Bhardwaj R; Ponsard B; Sarilar M; Wolterbeek B; Denkova A; Serra-Crespo P
Appl Radiat Isot; 2020 Feb; 156():108986. PubMed ID: 31786419
[TBL] [Abstract][Full Text] [Related]
18. Preparation and in vitro stability of (n,gamma) yttrium-90 hydroxyapatite.
Khalid M; Mushtaq A
Appl Radiat Isot; 2005 Apr; 62(4):587-90. PubMed ID: 15701413
[TBL] [Abstract][Full Text] [Related]
19. Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.
Miao Y; Fisher DR; Quinn TP
Nucl Med Biol; 2006 Aug; 33(6):723-33. PubMed ID: 16934691
[TBL] [Abstract][Full Text] [Related]
20. A review of advances in the last decade on targeted cancer therapy using
Chakravarty R; Chakraborty S
Am J Nucl Med Mol Imaging; 2021; 11(6):443-475. PubMed ID: 35003885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
